File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1111/j.1440-1746.2005.04167.x
- Scopus: eid_2-s2.0-33645923112
- WOS: WOS:000234896400007
- Find via
Supplementary
-
Bookmarks:
- CiteULike: 2
- Citations:
- Appears in Collections:
Conference Paper: CYP2C19 genotype and the PPIs - Focus on rabeprazole
Title | CYP2C19 genotype and the PPIs - Focus on rabeprazole |
---|---|
Authors | |
Keywords | Acid-Related Disorders Consistent Inhibition Cyp4502c19 Genetic Polymorphism Rabeprazole |
Issue Date | 2005 |
Publisher | Wiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH |
Citation | Journal Of Gastroenterology And Hepatology, 2005, v. 20 SUPPL. 3, p. S22-S28 How to Cite? |
Abstract | Amongst all the proton pump inhibitors (PPI), the hepatic metabolism of rabeprazole is least dependent on the CYP4502C19 system. Rabeprazole is therefore the PPI least affected by CYP4502C19 genetic polymorphism. This unique feature of rabeprazole complements rabeprazole's fast onset of action, and may lead to profound and consistent inhibition of gastric acid secretion in the treatment of acid-related disorders. © 2005 Blackwell Publishing Asia Pty Ltd. |
Persistent Identifier | http://hdl.handle.net/10722/163563 |
ISSN | 2023 Impact Factor: 3.7 2023 SCImago Journal Rankings: 1.179 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lim, PWY | en_US |
dc.contributor.author | Goh, KL | en_US |
dc.contributor.author | Wong, BCY | en_US |
dc.date.accessioned | 2012-09-05T05:37:25Z | - |
dc.date.available | 2012-09-05T05:37:25Z | - |
dc.date.issued | 2005 | en_US |
dc.identifier.citation | Journal Of Gastroenterology And Hepatology, 2005, v. 20 SUPPL. 3, p. S22-S28 | en_US |
dc.identifier.issn | 0815-9319 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/163563 | - |
dc.description.abstract | Amongst all the proton pump inhibitors (PPI), the hepatic metabolism of rabeprazole is least dependent on the CYP4502C19 system. Rabeprazole is therefore the PPI least affected by CYP4502C19 genetic polymorphism. This unique feature of rabeprazole complements rabeprazole's fast onset of action, and may lead to profound and consistent inhibition of gastric acid secretion in the treatment of acid-related disorders. © 2005 Blackwell Publishing Asia Pty Ltd. | en_US |
dc.language | eng | en_US |
dc.publisher | Wiley-Blackwell Publishing Asia. The Journal's web site is located at http://www.blackwellpublishing.com/journals/JGH | en_US |
dc.relation.ispartof | Journal of Gastroenterology and Hepatology | en_US |
dc.subject | Acid-Related Disorders | en_US |
dc.subject | Consistent Inhibition | en_US |
dc.subject | Cyp4502c19 Genetic Polymorphism | en_US |
dc.subject | Rabeprazole | en_US |
dc.title | CYP2C19 genotype and the PPIs - Focus on rabeprazole | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Wong, BCY:bcywong@hku.hk | en_US |
dc.identifier.authority | Wong, BCY=rp00429 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1111/j.1440-1746.2005.04167.x | en_US |
dc.identifier.scopus | eid_2-s2.0-33645923112 | en_US |
dc.identifier.hkuros | 117711 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-33645923112&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 20 | en_US |
dc.identifier.issue | SUPPL. 3 | en_US |
dc.identifier.spage | S22 | en_US |
dc.identifier.epage | S28 | en_US |
dc.identifier.isi | WOS:000234896400007 | - |
dc.publisher.place | Australia | en_US |
dc.identifier.scopusauthorid | Lim, PWY=7202592290 | en_US |
dc.identifier.scopusauthorid | Goh, KL=7201860992 | en_US |
dc.identifier.scopusauthorid | Wong, BCY=7402023340 | en_US |
dc.identifier.citeulike | 3012570 | - |
dc.identifier.issnl | 0815-9319 | - |